Abstract |
The efficacy of zolmitriptan ( Zomig, 311C90), a 5-hydroxytryptamine (5HT)1B/1D receptor agonist, in the acute oral treatment of migraine was evaluated in an extensive clinical trial program. Four randomized, placebo-controlled studies (total 2480 patients) were performed; data from two of these trials established that a 2.5 mg dose was on the shoulder of the dose-response curve (2-h headache response rate 64%), showing similar efficacy to the 5 mg dose (67%). In this program, the efficacy of zolmitriptan was not influenced by the pretreatment headache duration; the presence of aura preceding the headache, migraine associated with menses or migraine upon awakening; or by concomitant use of oral contraceptives or antidepressants. In addition, zolmitriptan 5 mg proved consistently effective in the treatment of multiple migraine attacks for up to 1 year. Zolmitriptan reduced the incidence of nausea, photophobia and phonophobia, reduced impairment of normal activity and demonstrated positive effects on patients' quality of life. Thus, zolmitriptan is a highly effective acute oral antimigraine therapy, with 2.5 mg providing the optimal balance between efficacy and tolerability.
|
Authors | J Schoenen, J Sawyer |
Journal | Cephalalgia : an international journal of headache
(Cephalalgia)
Vol. 17 Suppl 18
Pg. 28-40
(Oct 1997)
ISSN: 0333-1024 [Print] England |
PMID | 9399015
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Oxazoles
- Oxazolidinones
- Serotonin Receptor Agonists
- Tryptamines
- zolmitriptan
- Sumatriptan
|
Topics |
- Adolescent
- Adult
- Aged
- Child
- Dose-Response Relationship, Drug
- Female
- Humans
- Menstruation
(physiology)
- Middle Aged
- Migraine Disorders
(drug therapy, physiopathology)
- Nausea
(drug therapy)
- Oxazoles
(therapeutic use)
- Oxazolidinones
- Recurrence
- Serotonin Receptor Agonists
(therapeutic use)
- Sumatriptan
(therapeutic use)
- Treatment Outcome
- Tryptamines
|